NETWORK META-ANALYSIS DESIGN CONSIDERATIONS IN A COMPLEX AND RAPIDLY EVOLVING LANDSCAPE: A CASE STUDY IN FIRST-LINE (1L) ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)

被引：0
|
作者：
Popoff, E. [1 ]
Lozano-Ortega, G. [1 ]
Varol, N. [2 ]
Yuan, Y. [3 ]
Penrod, J. R. [3 ]
Goring, S. M. [1 ]
机构：
[1] Broadst HEOR, Vancouver, BC, Canada
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN275
引用
收藏
页码：S471 / S471
页数：1
相关论文
共 50 条
  • [1] COSTS OF CARE FOR FIRST-LINE (1L) TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): A REAL-WORLD CLAIMS ANALYSIS
    Kish, Jonathan
    Chopra, Dhruv
    Liassou, Djibril
    Lubinga, Solomon
    Hartman, John
    Feinberg, Bruce
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A437 - A438
  • [2] Real-world survival with first-line (1L) chemotherapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC)
    Waterhouse, D.
    Betts, K. A.
    Zhao, J.
    Rao, S.
    Gupte-Singh, K.
    Rutstein, M.
    Higashi, M. K.
    Schwartzberg, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 29 - U99
  • [3] First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis
    Zhang, Hongwei
    Chen, Jun
    Liu, Tingting
    Dang, Jun
    Li, Guang
    PLOS ONE, 2019, 14 (10):
  • [4] Comparative Effectiveness of First Line (1L) Therapies for Advanced Non-Small Cell Lung Cancer (aNSCLC): A Systematic Literature Review (SLR)
    Goring, S.
    Li, T.
    Gara, A.
    Varol, N.
    Korytowsky, B.
    Hertel, N.
    Baas, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S356 - S357
  • [5] The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
    Low, Jia Li
    Walsh, Robert J.
    Ang, Yvonne
    Chan, Gloria
    Soo, Ross A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [6] CLINICAL OUTCOMES OF FIRST-LINE (1L) TREATMENTS (Txs) IN LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (aNSCLC): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Reck, M.
    Soo, R. A.
    Coaquira, Castro J.
    Chaudhary, T.
    Finn, E.
    Xu, W.
    Zhan, L.
    VALUE IN HEALTH, 2024, 27 (06) : S44 - S44
  • [7] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227
    O'Byrne, K. J.
    Lee, K. H.
    Kim, S-W.
    Park, K.
    Nishio, M.
    Sakai, H.
    Ohe, Y.
    Fukuhara, T.
    Kang, J-H.
    Daga, H.
    Yu, C-J.
    Hotta, K.
    Tanaka, H.
    Takeda, M.
    Yokoyama, T.
    Nathan, F. E.
    Lee, J-S.
    ANNALS OF ONCOLOGY, 2020, 31 : S824 - S824
  • [8] First-Line Treatment Options for PD-L1-Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
    Peng, Ling
    Liang, Wen-Hua
    Mu, De-Guang
    Xu, Song
    Hong, Shao-Dong
    Stebbing, Justin
    Liang, Fei
    Xia, Yang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] What is the Optimal First-Line Regimen for EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis
    Zhang, W.
    Guo, Z.
    Ye, L.
    Chen, Z.
    Xu, K.
    Liu, X.
    Liu, Y.
    Wang, H.
    Zhao, L.
    Zhao, W.
    He, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S619 - S619
  • [10] First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis
    Hess, Lisa M.
    DeLozier, Amy M.
    Natanegara, Fanni
    Wang, Xiaofei
    Soldatenkova, Victoria
    Brnabic, Alan
    Able, Stephen L.
    Brown, Jacqueline
    JOURNAL OF THORACIC DISEASE, 2018, 10 (12) : 6677 - +
12345